231 related articles for article (PubMed ID: 20133772)
1. Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens.
Jordan KR; McMahan RH; Kemmler CB; Kappler JW; Slansky JE
Proc Natl Acad Sci U S A; 2010 Mar; 107(10):4652-7. PubMed ID: 20133772
[TBL] [Abstract][Full Text] [Related]
2. TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines.
Jordan KR; Buhrman JD; Sprague J; Moore BL; Gao D; Kappler JW; Slansky JE
Cancer Immunol Immunother; 2012 Oct; 61(10):1627-38. PubMed ID: 22350070
[TBL] [Abstract][Full Text] [Related]
3. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
4. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
5. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
[TBL] [Abstract][Full Text] [Related]
6. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
[TBL] [Abstract][Full Text] [Related]
7. Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor.
Buhrman JD; Jordan KR; Munson DJ; Moore BL; Kappler JW; Slansky JE
J Biol Chem; 2013 Nov; 288(46):33213-25. PubMed ID: 24106273
[TBL] [Abstract][Full Text] [Related]
8. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
[TBL] [Abstract][Full Text] [Related]
9. Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens.
Buhrman JD; Jordan KR; U'ren L; Sprague J; Kemmler CB; Slansky JE
Cancer Res; 2013 Jan; 73(1):74-85. PubMed ID: 23161490
[TBL] [Abstract][Full Text] [Related]
10. The use of HLA class I tetramers to design a vaccination strategy for melanoma patients.
Palmowski M; Salio M; Dunbar RP; Cerundolo V
Immunol Rev; 2002 Oct; 188():155-63. PubMed ID: 12445289
[TBL] [Abstract][Full Text] [Related]
11. Rapid assessment of recognition efficiency and functional capacity of antigen-specific T-cell responses.
Kohrt HE; Shu CT; Stuge TB; Holmes SP; Weber J; Lee PP
J Immunother; 2005; 28(4):297-305. PubMed ID: 16000947
[TBL] [Abstract][Full Text] [Related]
12. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses.
Lu J; Higashimoto Y; Appella E; Celis E
J Immunol; 2004 Apr; 172(7):4575-82. PubMed ID: 15034075
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
14. MHC-Optimized Peptide Scaffold for Improved Antigen Presentation and Anti-Tumor Response.
Tagliamonte M; Mauriello A; Cavalluzzo B; Ragone C; Manolio C; Luciano A; Barbieri A; Palma G; Scognamiglio G; Di Mauro A; Di Bonito M; Tornesello ML; Buonaguro FM; Vitagliano L; Caporale A; Ruvo M; Buonaguro L
Front Immunol; 2021; 12():769799. PubMed ID: 34745146
[TBL] [Abstract][Full Text] [Related]
15. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.
Saif JM; Vadakekolathu J; Rane SS; McDonald D; Ahmad M; Mathieu M; Pockley AG; Durrant L; Metheringham R; Rees RC; McArdle SE
Eur J Immunol; 2014 Apr; 44(4):994-1004. PubMed ID: 24338683
[TBL] [Abstract][Full Text] [Related]
16. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
Hanson HL; Kang SS; Norian LA; Matsui K; O'Mara LA; Allen PM
J Immunol; 2004 Apr; 172(7):4215-24. PubMed ID: 15034034
[TBL] [Abstract][Full Text] [Related]
17. Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides.
Filipazzi P; Pilla L; Mariani L; Patuzzo R; Castelli C; Camisaschi C; Maurichi A; Cova A; Rigamonti G; Giardino F; Di Florio A; Asioli M; Frati P; Sovena G; Squarcina P; Maio M; Danielli R; Chiarion-Sileni V; Villa A; Lombardo C; Tragni G; Santinami M; Parmiani G; Rivoltini L
Clin Cancer Res; 2012 Dec; 18(23):6485-96. PubMed ID: 23032742
[TBL] [Abstract][Full Text] [Related]
18. Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro.
Van Waes C; Monach PA; Urban JL; Wortzel RD; Schreiber H
Tissue Antigens; 1996 May; 47(5):399-407. PubMed ID: 8795140
[TBL] [Abstract][Full Text] [Related]
19. Multi-Epitope-Based Vaccines for Colon Cancer Treatment and Prevention.
Corulli LR; Cecil DL; Gad E; Koehnlein M; Coveler AL; Childs JS; Lubet RA; Disis ML
Front Immunol; 2021; 12():729809. PubMed ID: 34526999
[TBL] [Abstract][Full Text] [Related]
20. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
